Trial Search Results
Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The sponsors are testing an investigational treatment including two experimental drugs named KTE-C19 and Atezolizumab. The main purpose of this research study is to determine if the investigational products, KTE-C19 and Atezolizumab, when used concurrently and administered after participants receive a 3 day course of chemotherapy, is safe and effective in treating non-Hodgkin B-cell lymphoma and standard therapies available to treat the disease have not been effective.
Stanford is currently not accepting patients for this trial.